{"id":"NCT02274558","sponsor":"Neurocrine Biosciences","briefTitle":"A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2015-09","completion":"2016-07","firstPosted":"2014-10-24","resultsPosted":"2017-07-11","lastUpdate":"2017-07-11"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tardive Dyskinesia"],"interventions":[{"type":"DRUG","name":"NBI-98854","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NBI-98854 40 mg","type":"EXPERIMENTAL"},{"label":"NBI-98854 80 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.","primaryOutcome":{"measure":"Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6","timeFrame":"Baseline and Week 6","effectByArm":[{"arm":"Placebo","deltaMin":-0.1,"sd":0.4},{"arm":"Valbenazine 80mg","deltaMin":-3.2,"sd":0.4},{"arm":"Valbenazine 40mg","deltaMin":-1.9,"sd":0.4}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.0021"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":["31617235","30695293","29141124","28839342","28839341","28404690","28320223"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Somnolence","Suicidal ideation","Dry mouth"]}}